Abstract
Over the last two decades gene therapy has moved from preclinical to clinical studies for many diseases ranging from single gene disorders such as cystic fibrosis and Duchenne muscular dystrophy, to more complex diseases such as cancer and cardiovascular disorders. Gene therapy for severe combined immunodeficiency (SCID) is the most significant success story to date, but progress in many other areas has been significant. We asked 20 leaders in the field succinctly to summarize and comment on clinical gene therapy research in their respective areas of expertise and these are published in two parts in the Progress and Prospect series.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alton, E. Progress and Prospects: Gene Therapy Clinical Trials (Part 1). Gene Ther 14, 1439–1447 (2007). https://doi.org/10.1038/sj.gt.3303001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3303001
- Springer Nature Limited
Keywords
This article is cited by
-
Hispidulin: a promising anticancer agent and mechanistic breakthrough for targeted cancer therapy
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Exosomes and their Application in Biomedical Field: Difficulties and Advantages
Molecular Neurobiology (2018)
-
Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency
Scientific Reports (2018)
-
The retroviral vector family: something for everyone
Virus Genes (2017)
-
Correction of Pathological Morphofunctional Changes in the Mammalian Retina
Neurophysiology (2015)